Preliminary feasibility of pre-treatment F-18-PSMA-1007 PET/CT in dose prediction for Lu-177-PSMA-I&T therapy.

An Assessment of Time Toxicity in Patients Receiving [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Tolerability of [<sup>161</sup>Tb]Tb-SibuDAB in comparison to other PSMA-targeting radioligands in the preclinical setting.

Prognostic Value of [¹⁸F]FDG PET Combined with [⁶⁸Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [¹⁷⁷Lu]Lu-PSMA-617.

Clinical Trial Protocol for LPS-Boost: Intensified [¹⁷⁷Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.

Association of Early Same-Day Posttherapy Whole-Body SPECT/CT Using Visual RECIP 1.0 with Overall Survival During [¹⁷⁷Lu]Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer.

Efficacy, safety, and quality of life outcomes of [<sup>177</sup>Lu] Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a GRADE-assessed systematic review, meta-analysis and trial sequential analysis.